Personalized Therapy for Advanced Non-Small Cell Lung Cancer: From BATTLE to Master Protocols to Immunotherapy

Roy S. Herbst1,2

1Yale Cancer Center, New Haven, CT, USA,2Yale School of Medicine, New Haven, CT, USA,3Smilow Cancer Hospital, New Haven, CT, USA


The therapy for advanced non-small cell lung cancer has improved dramatically in recent years.  We have moved from an era of Cisplatin-based chemotherapy to the use of targeted therapy, immunotherapy, and their combinations. Of equal importance is the evolution of more personalized tissue-based therapy used to guide treatment choice. This lecture will chronicle the 10+ year history of the development of biopsy-based treatments for lung cancer, evolving from the initial BATTLE trials to the Umbrella and Master Protocols of today. The dawn of immunotherapy will be discussed along with efforts designed to administer it in a more targeted way with the development of novel biomarker and combinations based on the work of the Yale Cancer Center/Smilow Cancer Hospital SPORE research team.